Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements

Identified CCI-007 as a novel small molecule that displays rapid toxicity towards a subset of MLL-r, CALM-AF10 and SET-NUP214 leukemia cell lines

Research

Regular exercise improves the well-being of parents of children with cancer

Mental health benefits of a pedometer-based exercise intervention for parents of children with cancer were identified.

Research

Risk of cancer among children with birth defects: A novel approach

This novel approach aimed to prevent inflated hazard ratios arising from reverse causation, and allow identification of associations beyond those already...

Research

Confirmation of childhood acute lymphoblastic leukemia Variants, ARID5B and IKZF1, and interaction with parental environmental exposures

The polygenic nature of childhood ALL predisposition together with the timing of environmental triggers may hold vital clues for disease etiology.

News & Events

New drug hope for babies with leukaemia

Researchers at The Kids Research Institute Australia have discovered a new drug combination that could help improve survival rates for babies with leukaemia.

News & Events

A cell change that drives leukaemia

It is now known that the HOX11 gene is permanently activated in the leukaemia cells and it drives the disease.

News & Events

WA families to help find triggers for childhood leukaemia

West Australian families are being asked to play a vital role in a major new national study to unravel the causes of childhood leukaemia.

Research

It is more “unbalanced” than you think

Sébastien Malinge PhD Laboratory Head, Translational Genomics in Leukaemia, Senior Research Fellow (University of Western Australia), Adjunct Senior

Research

Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockade

Antibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4, programmed cell death protein/ligand 1 are approved for treatment of multiple cancer types. 

Research

Propofol, Anesthesia, and Neurocognitive Outcomes in Patients with Pediatric Leukemia: Are We Missing the Forest for the Trees?

Britta Regli-von Ungern-Sternberg AM FAHMS MD, PhD, DEAA, FANZA Chair of Paediatric anaesthesia, University of Western Australia; Consultant